Collaboration, License, and Other Agreements - China, Hong Kong and Macau (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2019 USD ($) installment	Dec. 31, 2021 USD ($)
Collaboration, License, Promotion and Other Commercial Agreements
Revenue	$ 108,637	$ 103,747	$ 303,397	$ 296,623
Collaborative arrangements revenue
Collaboration, License, Promotion and Other Commercial Agreements
Revenue	108,637	103,747	303,397	295,798
Sale of active pharmaceutical ingredient
Collaboration, License, Promotion and Other Commercial Agreements
Revenue				825
AstraZeneca
Collaboration, License, Promotion and Other Commercial Agreements
Milestone payment to be received by company upon milestone achievement			90,000
Collaborative arrangement, significant financing component, transaction price	2,600		$ 2,600
Amount of non-contingent arrangement consideration					$ 35,000
Non-contingent consideration installments | installment					3
Percentage of tiered royalties			20.00%
Collaborative arrangement, non-contingent installment payments receivable	25,000		$ 25,000
Collaborative arrangement, non-contingent receivable, current	10,000		10,000
Collaborative arrangement, non-contingent receivable, non-current	14,400		14,400			$ 24,000
AstraZeneca | Collaborative arrangement, collaboration and license agreements
Collaboration, License, Promotion and Other Commercial Agreements
Revenue	$ 144	219	484	629
AstraZeneca | Royalty
Collaboration, License, Promotion and Other Commercial Agreements
Revenue		$ 200	$ 500	400
AstraZeneca | Sale of active pharmaceutical ingredient
Collaboration, License, Promotion and Other Commercial Agreements
Revenue				$ 597